國家衛生研究院 NHRI:Item 3990099045/13313

NHRI > Institute of Biotechnology and Pharmaceutical Research > Ching-Chuan Kuo > Periodical Articles > Item 3990099045/13313

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/13313

Title:	Tea polyphenol epigallocatechin-3-gallate inhibits cell proliferation in a patient-derived triple-negative breast cancer xenograft mouse model via inhibition of proline-dehydrogenase-induced effects
Authors:	Lee, WJ;Cheng, TC;Yen, Y;Fang, CL;Liao, YC;Kuo, CC;Tu, SH;Lin, LC;Chang, HW;Chen, LC;Ho, YS
Contributors:	Institute of Biotechnology and Pharmaceutical Research;NHRI Graduate Student Program
Abstract:	Triple-negative breast cancers (TNBCs) lack specific targeted therapy options and have evolved into highly chemo-resistant tumors that metastasize to multiple organs. The present study demonstrated that the proline dehydrogenase (PRODH) mRNA level in paired (tumor vs. normal) human breast tissue samples (n ¼ 234) was 6.6-fold greater than normal cells (p ¼ 0.021). We established stable PRODH-overexpressing TNBC (HS578T) cells, and the malignant phenotypes were evaluated using soft agar colony formation and Transwell migration assays. The results demonstrated that PRODH induced epithelial-mesenchymal transition in cancer cells and increased cell proliferation. The present study found that the tea polyphenol epigallocatechin-3-gallate (EGCG) significantly inhibited PRODH and its regulated proteins, such as alpha-smooth muscle actin (alpha-SMA) expression in TNBC cells. These findings support the targeting of the PRODH signaling pathway as a potential therapeutic strategy in preventing cancer cell metastasis. The patient-derived xenograft (PDX) mouse model is highly relevant to real human tumor growth. We established a TNBC-PDX (F4, n ¼ 4 in each group) mouse model. The PDX mice were treated with EGCG (50 mg/kg), and the results indicated that EGCG significantly inhibited PDX tumor growth (p ¼ 0.013). These experiments provide additional evidence to evaluate the antitumor effects of EGCG-induced PRODH inhibition for clinical therapeutic application, especially in TNBC patients.
Date:	2021-03-15
Relation:	Journal of Food and Drug Analysis. 2021 Mar 15;29(1):113-127.
Link to:	http://dx.doi.org/10.38212/2224-6614.3230
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1021-9498&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000629289300009
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85102582100
Appears in Collections:	[Ching-Chuan Kuo] Periodical Articles [Others] Periodical Articles

Files in This Item:

File	Description	Size	Format
SCP85102582100.pdf		3847Kb	Adobe PDF	311	View/Open

Loading...